NCT06276491 2026-03-17
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Recruiting
Xencor, Inc.
Fondazione del Piemonte per l'Oncologia
HiFiBiO Therapeutics
University of Texas Southwestern Medical Center
BioNTech SE